NCT06124378 2025-09-24
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
First Affiliated Hospital of Guangxi Medical University
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT06709885 2024-11-29
HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Recruiting
NCT06218888 2024-01-23
A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT05231850 2022-02-09
A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage â…¡ and Stage â…¢ Colon Cancer and dMMR/MSI.
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT04777162 2021-03-04
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Peking University
Phase 2 Unknown